Technology Transfer

Technology transfer success: US approval for bleeding disorder drug

“VONVENDI [von Willebrand factor (Recombinant)]”, the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration. It is the first, and so far the only, recombinant protein for the treatment of von Willebrand disease, and offers those affected […]

Drug against aggressive leukemia gets approval for Europe

The drug Blincyto (Blinatumomab) has now been approved by the European Medicines Agency. Blinatumomab is used to treat patients with a very aggressive form of blood cancer, and is the result of work carried out at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) over ten years ago. Start-up company Micromet […]

BIH funds new projects at the MDC

In scientific research the discovery of a new type of molecule that regulates the flow of information from genes to proteins has a big impact. Such new regulators are top candidates to tackle human diseases at their roots as they govern on one of the most fine-tuned cellular processes. Today’s rapid development in technology enables […]